Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
Completed · Phase 1 · NCT03739931
Conditions: Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
At a glance
- Research payments reported, 2025
- $358,801
- U.S. investigators named
- 7
- Sites paid
- 6
- Planned or actual enrollment
- 134
About the trial
- Sponsor
- ModernaTX, Inc. (with AstraZeneca)
- Tested
- mRNA-2752 (biological), Durvalumab (biological)
- Dates
- Started 2018-11-27; completion 2025-08-01
- Results posted
- Not yet
The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.
From ClinicalTrials.gov, last updated 2025-08-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $358,801 in research payments for this study in 2025 (27 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Adil Daud, MD Medical Oncology · Tampa, FL
- Manish R. Patel, MD Medical Oncology · Sarasota, FL
- Randy Sweis Hematology & Oncology · Chicago, IL
- Kartik Sehgal, MD Hematology & Oncology · Boston, MA
- Ryan J. Sullivan, MD Internal Medicine · Cambridge, MA
- Thomas U. Marron, M.D. PH.D. Medical Oncology · New York, NY
- Shivaani Kummar Medical Oncology · Portland, OR
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sarah Cannon Research Institute LLC $201,530
- The University of Chicago $93,232
- Dana Farber Cancer Institute Inc $43,564
- Ohsu Hospital and Clinics, OR $11,597
- University of California Davis Medical Center, CA $7,378
- Icanh School of Medicine $1,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.